Neil Kumar at Endpoints' #BIO22 panel (Photo: Endpoints News)
July 26, 2022 07:30 AM EDTUpdated 09:26 AM
R&D

Tar­get­ing Bio­Mar­in's new drug fran­chise, Bridge­Bio CEO Neil Ku­mar cel­e­brates an in­ter­im win. But is it good enough?

John Carroll

Editor & Founder

Over the past few months, Bridge­Bio CEO Neil Ku­mar has been cut­ting deep to re­pair the dam­age of a crush­ing Phase III fail at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times